NZ595492A - Improved Process for the Preparation of Lenalidomide - Google Patents

Improved Process for the Preparation of Lenalidomide

Info

Publication number
NZ595492A
NZ595492A NZ595492A NZ59549210A NZ595492A NZ 595492 A NZ595492 A NZ 595492A NZ 595492 A NZ595492 A NZ 595492A NZ 59549210 A NZ59549210 A NZ 59549210A NZ 595492 A NZ595492 A NZ 595492A
Authority
NZ
New Zealand
Prior art keywords
lenalidomide
isoindol
dione
piperidine
dihydro
Prior art date
Application number
NZ595492A
Other languages
English (en)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Suresh Hasbe
Shreyas Bhandari
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ595492A publication Critical patent/NZ595492A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
NZ595492A 2009-03-02 2010-03-01 Improved Process for the Preparation of Lenalidomide NZ595492A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
NZ595492A true NZ595492A (en) 2013-07-26

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595492A NZ595492A (en) 2009-03-02 2010-03-01 Improved Process for the Preparation of Lenalidomide

Country Status (16)

Country Link
US (1) US8946265B2 (enExample)
EP (1) EP2403845B1 (enExample)
JP (1) JP5727944B2 (enExample)
CN (1) CN102414196A (enExample)
AU (1) AU2010220204B2 (enExample)
CA (1) CA2753241C (enExample)
CY (1) CY1115376T1 (enExample)
DK (1) DK2403845T3 (enExample)
ES (1) ES2487215T3 (enExample)
HR (1) HRP20140686T1 (enExample)
NZ (1) NZ595492A (enExample)
PL (1) PL2403845T3 (enExample)
PT (1) PT2403845E (enExample)
SI (1) SI2403845T1 (enExample)
SM (1) SMT201400100B (enExample)
WO (1) WO2010100476A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
ES2705244T3 (es) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
CA2842316A1 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)­piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
CN105228700A (zh) * 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
US20170107193A1 (en) * 2014-04-26 2017-04-20 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
ES2733813T3 (es) * 2014-08-19 2019-12-03 Synthon Bv Proceso para preparar una forma cristalina de lenalidomida
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
EP3393457A1 (en) 2015-12-22 2018-10-31 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
EP3687987A4 (en) * 2017-09-27 2021-03-24 Biocon Limited CRYSTALLINE FORMS OF LENALIDOMIDE
WO2019138424A1 (en) * 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体（上海）有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ554068A (en) 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
EP2136896B1 (en) 2007-04-16 2015-01-21 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating n-glycans
JP2011506950A (ja) 2007-12-14 2011-03-03 ジェネリクス・（ユーケー）・リミテッド クロピドグレルを分析するためのｈｐｌｃ法
KR20100124710A (ko) 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
CA2741927A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
SMT201400100B (it) 2014-11-10
PT2403845E (pt) 2014-08-04
AU2010220204A1 (en) 2011-10-20
JP2012519207A (ja) 2012-08-23
ES2487215T3 (es) 2014-08-20
PL2403845T3 (pl) 2014-09-30
CA2753241A1 (en) 2010-09-10
EP2403845A2 (en) 2012-01-11
DK2403845T3 (da) 2014-08-04
SI2403845T1 (sl) 2014-09-30
US8946265B2 (en) 2015-02-03
EP2403845B1 (en) 2014-04-30
CA2753241C (en) 2015-06-16
CY1115376T1 (el) 2017-01-04
JP5727944B2 (ja) 2015-06-03
WO2010100476A2 (en) 2010-09-10
US20120071509A1 (en) 2012-03-22
CN102414196A (zh) 2012-04-11
AU2010220204B2 (en) 2015-10-08
WO2010100476A3 (en) 2011-06-16
HRP20140686T1 (hr) 2014-09-26

Similar Documents

Publication Publication Date Title
TW200730175A (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
MY206244A (en) Anti-muc1 antibody-drug conjugate
PL2046331T3 (pl) Zastosowanie 3-(4-amino-1-okso-1,3-dihydroizoindol-2-ilo)-piperydyno-2,6-dionu do leczenia chłoniaka z komórek płaszcza
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
PH12012502512A1 (en) 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors
LTPA2017015I1 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
ZA202007564B (en) Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
NZ728392A (en) High dosage strength tablets of rucaparib
JO3754B1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
WO2010100476A3 (en) Improved process
CA198882S (en) Heating bowl for electronic hookah
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
PH12012500788A1 (en) Compositions and methods for treating colitis
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
JP2009507030A5 (enExample)
IL304617A (en) Inductive heating arrangement for heating spray-forming substrates
EP2477975A4 (en) SOLID FORMS OF 3- (4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL) -PIPERIDINE-2,6-DION AND METHOD OF MANUFACTURING THEREOF
MX2023010897A (es) Antagonista del receptor de melanocortina subtipo 2 (mc2r) para el tratamiento de enfermedades.
MX2010004017A (es) 5-cianotienopiridinas para el tratamiento de tumores.
ZA202409847B (en) Gastro-resistant controlled release oral dosage forms
MX2017011981A (es) Terapias novedosas para cancer.
EP3919072A4 (en) PREPARATION OF A CANCER VACCINE
WO2010117756A3 (en) Substituted benzimidazole pharmaceutical formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2017 BY DENNEMEYER SA

Effective date: 20140214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY RENEWALS TEAM

Effective date: 20170325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2019 BY RENEWALS TEAM

Effective date: 20180210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2020 BY RENEWALS TEAM

Effective date: 20190105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY RENEWALS TEAM

Effective date: 20200224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY IPAN GMBH

Effective date: 20210218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY IPAN GMBH

Effective date: 20220215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY IPAN GMBH

Effective date: 20230215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY IPAN GMBH

Effective date: 20240216

ASS Change of ownership

Owner name: TIANISH LABORATORIES PRIVATE LIMITED, IN

Effective date: 20250417

LAPS Patent lapsed